Medical-necessity and step-therapy denials are appealable with documentation
Semaglutide works well for steady, sustainable weight loss, while Tirzepatide may deliver faster results
As early as 2002, Fulghesu et al
Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos, says Ania Jastreboff, MD, PhD, professor of medicine & pediatrics (endocrinology) at the Yale School of Medicine, director of the Yale Obesity Research Center, and lead investigator, in a release
Boston University and UMass Memorial Health said they will stop covering GLP-1s for weight loss next year, with the latter saying it spent $20 million on the drugs just in the past year
Tanriverdi, G